Aurobindo Pharma Limited is pleased to announce that it has received the final approval for Lamotrigine Tablets (Chewable, Dispersible) 5mg and 25mg from the US Food & Drug Administration (USFDA).
Lamotrigine Tablets 5mg and 25mg is generic equivalent to Lamictal® CD Tablets 5mg and 25mg of GlaxoSmithKline. Lamotrigine tablet falls under the CNS (Central Nervous System) segment and is indicated as adjunctive therapy for partial seizures and generalized seizures of Lennox - Gastaut syndrome in patients aged 2 years and older, and for conversion to monotherapy in adults with partial seizures who are receiving treatment with a single enzyme-inducing antiepileptic drug. The product would be launched soon.
Aurobindo now has a total of 107 ANDA approvals (78 Final approvals and 29 Tentative approvals) from USFDA.
The stock was trading at Rs.838, up by Rs.29.70 or 3.67%. The stock hit an intraday high of Rs.839 and low of Rs.810.
The total traded quantity was 11613 compared to 2 week average of 23972.
|
